Back to search

The University of Edinburgh

Defining the functional enhancers co-bound by SOX2 and SOX9 in glioblastoma

Abstract

dc:description.abstract

SOX2 and SOX9 are two key regulatory transcription factors highly expressed in glioblastoma multiforme (GBM) and are thought to be critical in establishing and sustaining neural stem cell-like identity. However, their downstream transcriptional targets and how these two factors cooperate remain unknown. Candidate enhancers co-bound by SOX2 and SOX9 have recently been revealed by the ChIP-seq profiling across seven patient-derived GBM stem cell lines (GSCs) (Pollard lab, unpublished). Here we characterise SOX2 and SOX9 candidate autoregulatory enhancers and determine if they are functional. Ten candidate enhancers that were identified within the SOX2 locus (candidate autoregulatory enhancers) were mutated using CRISPR in different GSCs and SOX2 expression levels were assessed. Using both SOX2-mCherry knock-in fusion reporter GSCs and western blotting, three candidate enhancers (S2-E3, S2-E5 and S2-E7) showed a reduction in levels of SOX2 protein in populations of CRISPR treated cells. Next, focussing on S2-E5 due to its known roles in squamous cell carcinomas, we established clonal GSC lines in which this enhancer was mutated. Clones were expanded and genotyped by PCR to confirm deletion of S2-E5 alleles. We found that enhancer loss was associated with SOX2 downregulation at protein levels (western blot and immunocytochemistry) and analysed whether this could impact GBM self-renewal and tumorigenicity. We revealed that SOX2 was indeed reduced in the validated clones, and these showed a lower growth rate than the controls. In addition to the genetic loss-of-function studies, candidate enhancers located in the SOX2 and SOX9 gene loci were amplified and cloned into mNeonGreen-reporter plasmids and used in enhancer activity assays. Each of the plasmids (18 in total) were individually transfected into different GSCs by lipofection and activity was determined by flow cytometry. These experiments identified a subset of candidate enhancers that were active across all, or most, GSCs tested (S2-E3, S2-E7, S2-E10, S9-E1 and S9-E8); others were line-specific in their activity (S2-E5 and S9-E6 were active in E55 and G7 respectively), indicating cell line-dependent activity. Finally, for a set of functional enhancers (S2-E3, S2-E5, S2-E7 and S9-E1), we created a tiled series of 160 bp fragments spanning the enhancers and identified a smaller core region that was still functional – an important step to their use for future viral vector-based applications. In conclusion, here we have identified functional enhancers that modulate the expression of SOX2 in GSCs and are functionally important to sustain proliferation. These SOX2 functional enhancer fragments will be used in future studies to explore SOX2 and SOX9 biochemical cooperativity and for applications in gene therapy where they can be deployed in viral vectors for the expression of anti-cancer payloads.

Degree

thesis:*
Grantor dc:publisher
The University of Edinburgh
Year dc:date.issued
2023

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Gassó Alern, Adrià
Advisors dc:contributor.advisor
  • Pollard, Steven
  • Soufi, Abdenour

Subjects

dc:subject × 5

Rights

Language dc:language.iso
en

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
University of Edinburgh
Base URL
era.ed.ac.uk/server/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Gassó Alern, Adrià. Defining the functional enhancers co-bound by SOX2 and SOX9 in glioblastoma. The University of Edinburgh, 2023. https://hdl.handle.net/1842/43071